Brainstorm Cell Therapeutics Inc
BCLI1.170USD
-0.030-2.50%
Market hours （ET）Quotes delayed by 15 min
9.26MMarket Cap
LossP/E TTM
More Details of Brainstorm Cell Therapeutics Inc Company
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Company Info
Ticker SymbolBCLI
Company nameBrainstorm Cell Therapeutics Inc
IPO dateMay 28, 2003
CEOMr. Chaim Lebovits
Number of employees27
Security typeOrdinary Share
Fiscal year-endMay 28
Address1325 Avenue Of Americas
CityNEW YORK
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code10019
Phone12014880460
Websitehttps://brainstorm-cell.com/
Ticker SymbolBCLI
IPO dateMay 28, 2003
CEOMr. Chaim Lebovits
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 27
Updated: Sun, Jul 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.30%
Hedge Fund
9.03%
Investment Advisor
3.58%
Holding Company
1.68%
Investment Advisor/Hedge Fund
0.73%
Research Firm
0.04%
Other
70.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
115
2.33M
29.37%
+771.43K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
2023Q2
123
1.03M
39.20%
+17.38K
2023Q1
150
979.29K
38.21%
+5.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
690.67K
8.7%
+690.67K
--
Mar 31, 2025
Ruck (Matthew J)
275.84K
3.47%
+275.84K
--
Nov 13, 2024
Ness (Kevin Dean)
204.00K
2.57%
-40.00K
-16.39%
Feb 14, 2024
Lebovits Chaim
200.96K
2.53%
--
--
Apr 01, 2025
Caldwell Sutter Capital, Inc
157.01K
1.98%
--
--
Mar 31, 2025
ACC International Holdings, Ltd.
133.39K
1.68%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
1%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.86%
--
--
Apr 01, 2025
Geode Capital Management, L.L.C.
58.16K
0.73%
+5.66K
+10.79%
Mar 31, 2025
Hartounian (Hartoun)
52.00K
0.66%
--
--
Apr 01, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Date
Type
Ratio
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
